| Literature DB >> 32139013 |
Gary A Ulaner1, C Ola Landgren2.
Abstract
Fluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) allows evaluation of elevated glucose metabolism in malignancies. There has been increasing interest in FDG PET/CT for plasma cell disorders since the International Myeloma Working Group outlined multiple applications of this imaging modality, including distinguishing smoldering myeloma from active multiple myeloma, confirmation of solitary plasmacytoma, and multiple indications in patients with known multiple myeloma, including determining extent of initial disease, monitoring therapy response, and detection of residual disease following therapy. The field of molecular imaging is now shifting focus from evaluation of metabolism to targeted evaluation of specific tumor markers. Targeted PET imaging targeted of CXCR4 and CD38 has advanced into translational clinical trials, bringing us closer to powerful imaging options for myeloma. In this review we discuss the current applications of FDG PET/CT in plasma cell disorders, as well as advances in targeted PET imaging.Entities:
Keywords: 18F-fluorodeoxyglucose (FDG); Multiple myeloma; Positron emission tomography (PET); immunoPET
Mesh：
Substances：
Year: 2020 PMID： 32139013 PMCID： PMC7410322 DOI： 10.1016/j.beha.2020.101148
Source DB: PubMed Journal: Best Pract Res Clin Haematol ISSN： 1521-6926 Impact factor: 3.020